MedTrace Logo

Speech-derived Digital Biomarkers Study

NCT06994767 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-01-13

No results posted yet for this study

Summary

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Alzheimer Disease

Interventions

OTHER

The Canary Application

The CANARY application will use clinically validated survey instruments and voice recordings to measure user MCI status /Alzheimer's data. These tests are designed to evaluate a user's voice characteristics and potentially identify disease-specific patterns.

Sponsors & Collaborators

  • Canary Speech Inc.

    collaborator UNKNOWN

  • Hackensack Meridian Health

    lead OTHER

Principal Investigators

  • Sakshi Jain, MD · Hackensack Meridian Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-19
Primary Completion
2026-01-09
Completion
2026-01-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06994767 on ClinicalTrials.gov